mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer

NCT03043729 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

119

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer
Rectosigmoid Cancer

Interventions

DRUG: Oxaliplatin
DRUG: 5-FU
DRUG: Leucovorin
BIOLOGICAL: Aflibercept

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]
[object Object]